A case-control study on genetic polymorphism of CYP17 MspA (1) I and its association with endometrial cancer risk
Gao, J.; Xiang, Y-bing.; Xu, W-hong.; Cheng, J-rong.; Cai, Q-yin.; Shu, X-ou.; Gao, Y-tang.
Zhonghua Zhong Liu Za Zhi 29(4): 266-269
2007
ISSN/ISBN: 0253-3766 PMID: 17760252 Document Number: 605804
Objective To assess whether the polymorphisms of CYP17 MspA(1)I are associated with the susceptibility of endometrial cancer. Methods The allelic discrimination of the CYP17A1 gene polymorphisms were assessed with the ABI PRISM 7900 Sequence Detection Systems using TaqMan genotyping assay. Unconditional logistic regression was applied to assess odds ratio and 95% CI and evaluate the association between different genotypes and endometrial cancer development. Results The frequencies of wild-type, heterozygote and homozygote for the CYP17 MspA(1)I in control women in Shanghai were 17.8%, 49.3% and 32.9%, respectively. No significant difference was found in the distribution of various genotypes of CYP17 MspA(1)I between patients and controls. Pregnancy was associated with reduced risk of endometrial cancer in pre-menopausal women with A2 allele, OR = 0.66, 95% CI: 0.44 - 0.99. In postmenopausal women with A2 allele, more pregnancies (> 2) and shorter time of menstruation (<= 32 yrs) were associated with reduced risk of endometrial cancer. Conclusion No significant relationship was found between GYP17 MspA(1)I genotypes and endometrial cancer risk.